Literature DB >> 17272627

The use of statins in pediatrics: knowledge base, limitations, and future directions.

Brook Belay1, Peter F Belamarich, Catherine Tom-Revzon.   

Abstract

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, effectively reduce coronary morbidity and mortality in high-risk adults. They are also some of the most widely prescribed medications in the United States. Their use in pediatrics, however, remains circumscribed. In this article we review the cholesterol hypothesis and focus on the knowledge base of the use of statins in adults and children. We pay particular attention to the known effects of statins in primary and secondary prevention of cardiovascular events. The toxicities of statins and their limitations in pediatrics are then considered. The use of statins in conjunction with noninvasive modalities of assessing atherosclerotic burden are also reviewed. Finally, we suggest methods to advance the use of statins in childhood that introduce their potential benefits to those individuals at highest risk for future events.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17272627     DOI: 10.1542/peds.2006-0787

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  17 in total

1.  Torturing a blood vessel.

Authors:  Cam Patterson
Journal:  Nat Med       Date:  2009-02       Impact factor: 53.440

Review 2.  Cholesterol screening and statin use in children: a literature review.

Authors:  Karen King; Alan Macken; Ophelia Blake; Clodagh S O'Gorman
Journal:  Ir J Med Sci       Date:  2018-06-01       Impact factor: 1.568

3.  Use of statins for dyslipidemia in the pediatric population.

Authors:  Lea S Eiland; Paige K Luttrell
Journal:  J Pediatr Pharmacol Ther       Date:  2010-07

4.  Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease.

Authors:  Chao Duan; Zhong-Dong Du; Yu Wang; Li-Qun Jia
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

5.  Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?

Authors:  Harsha Prasada Lashkari; Donna Lancaster; Ayad Atra; Michael P Champion; Mary M Taj
Journal:  Int J Hematol       Date:  2011-11-08       Impact factor: 2.490

Review 6.  Risks and benefits of statin use in young people with type 1 diabetes.

Authors:  Petter Bjornstad; R Paul Wadwa
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

Review 7.  Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.

Authors:  Jonathan Wagner; J Steven Leeder
Journal:  Pediatr Clin North Am       Date:  2012-08-22       Impact factor: 3.278

Review 8.  Vascular health in children and adolescents: effects of obesity and diabetes.

Authors:  Kevin R Short; Piers R Blackett; Andrew W Gardner; Kenneth C Copeland
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

Review 9.  Lipoprotein metabolism in chronic renal insufficiency.

Authors:  Jeffrey M Saland; Henry N Ginsberg
Journal:  Pediatr Nephrol       Date:  2007-03-28       Impact factor: 3.714

Review 10.  Dyslipidemia in youth with diabetes: to treat or not to treat?

Authors:  David M Maahs; R Paul Wadwa; Franziska Bishop; Stephen R Daniels; Marian Rewers; Georgeanna J Klingensmith
Journal:  J Pediatr       Date:  2008-10       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.